hydroxyindoleacetic acid has been researched along with lx1032 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anthony, LB; Banks, P; Bergsland, E; Caplin, ME; Fleming, D; Grande, E; Hörsch, D; Jackson, S; Kulke, MH; Kunz, PL; Lapuerta, P; Lombard-Bohas, C; Öberg, K; Pavel, M; Sands, AT; Valle, JW; Warner, RR; Welin, S; Zambrowicz, B | 1 |
| Anthony, LB; Benavent, M; Fleming, D; Fleming, R; Garcia-Carbonero, R; Gross, DJ; Hörsch, D; Jiang, W; Kassler-Taub, K; Kulke, MH; Kunz, PL; Lapuerta, P; Pavel, M; Perros, P; Srirajaskanthan, R; Warner, RRP; Wason, S; Weickert, MO | 1 |
2 trial(s) available for hydroxyindoleacetic acid and lx1032
| Article | Year |
|---|---|
Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.
Topics: Aged; Antineoplastic Agents, Hormonal; Defecation; Diarrhea; Double-Blind Method; Female; gamma-Glutamyltransferase; Gastrointestinal Agents; Humans; Hydroxyindoleacetic Acid; Male; Malignant Carcinoid Syndrome; Middle Aged; Nausea; Octreotide; Peptides, Cyclic; Phenylalanine; Pyrimidines; Somatostatin; Tryptophan Hydroxylase | 2017 |
Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Diarrhea; Double-Blind Method; Female; Humans; Hydroxyindoleacetic Acid; Male; Malignant Carcinoid Syndrome; Middle Aged; Phenylalanine; Pyrimidines; Somatostatin; Treatment Outcome | 2018 |